Pharmalicensing brings you advice, commentary and analysis from industry experts.
"I attend many conferences in my role at GSK but I certainly found this event to be of a very high quality and extremely useful"
Kate Burt, Director, Commercial Alliances and Transactions, Worldwide Business Development
GlaxoSmithKline
Industry Under Pressure
According to the latest figures released by Datamonitor, drug development is growing more and more expensive, now estimated to be $800 million-$1 billion per product. Each day a launch is delayed can cost you up to $23 million in lost sales in the USA alone, and $37,000 per day in additional development costs.
Given that the FDA approved just 17 new molecular entities and 2 biologic license applications in 2007, the lowest number recorded since 1983, you need to make sure you make the right choices in this difficult climate to ensure continued growth for your organisation.
Your Solution
If you are anything like our delegates, you find it is getting more and more difficult to identify the events which will offer you real value and justify your time out of the office. Bio-partnering events should be about meeting the right people for your business and having the opportunity to assess potential and develop relationships.
That is why senior management goes back time and time again to BioBusiness Network, which offers the complete package to make sure you uncover these opportunities first: an optimal mix of formal and informal networking combined with industry strategy and competitive insight from industry leaders.
Networking
Of course, when you attend an exclusive conference you want to be sure you really benefit from that high level of seniority, which is why BioBusiness Network has been carefully designed to offer you maximum formal and informal networking time. Use the improved partnering website to organise up to 10 formal one-to-ones each day and cement successful relationships during frequent coffee breaks, drinks receptions, roundtables and dinners.
Your objective in attending any conference is to meet with potential partners, develop existing relationships and leave with a substantial number of leads to pursue further.
Based on over 500 hundred hours of research with the industry, the BioBusiness Network agenda has been carefully refined to ensure you meet and exceed your networking goals.
One-to-ones. You will have access to the BioBusiness Network online partnering website up to 6 weeks before the event. This gives you time to pinpoint the delegates you want to meet and to plan out your schedule to ensure you plan up to 10 effective formal meetings per day.
Breaks and lunches. In response to delegate requests, this year we are offering even more informal networking time over lunch and coffee. With plenty of informal meeting space throughout the conference area, you can continue interesting discussions or grab 15 valuable minutes with your ideal partner.
Dinner. This is where the BioBusiness Network exclusivity really comes into its own. No other conference of this type offers you the chance to network with so many high profile speakers and delegates at one dinner.
Drinks. The perfect way to wind down after a long day and boost your informal networking.
Roundtables. Always a popular part of the conference, you now have the chance to join discussion tables throughout the event as each afternoon session on day one will be followed by the chance to join the discussion and increase your networking capability.
High Profile Agenda
No other conference offers such an intimate and exclusive atmosphere in which to meet your peers and do effective business.
Whatever your focus, information on your potential partners and competitors is invaluable. BioBusiness Network is the only conference to offer you 360° visibility on the industry you work in, with first hand deal insight from biotechs and pharma, overviews from regulatory bodies, coaching from independent experts and the hottest new innovation from across the globe.
Agenda Highlights For 2008 Include
• Dr Simon Best, ex-Chair of the BIA and World Economic Forum-nominated Global Leader of Tomorrow, who will give a comprehensive overview of the factors which will impact your industry in the next few years and detailing the solutions which will keep you one step ahead.
• Elias Papatheodorou, CEO of Novosom and pioneer in delivery of DNA-based technologies, who has brought together a panel of RNA experts to discuss the potential and practicalities of this hot area.
• Sarah Garner, Associate Director of Research & Development and NICE, who will share insights into NICE processes and highlight the key hurdles recent submissions have faced.
As always, BioBusiness Network will also provide you with the inside story on the biggest deals of the last few months, including Roche/Piramed, Wyeth/Haptogen and Merck Serono/Archemix.
7 reasons to attend BioBusiness Network 2008
1) Over 40% of BioBusiness Network delegates are c-level and a further 30% are directors or regional heads, meaning you meet the decision makers who will shape your business for 2009
2) We are bringing together the leading players in key emerging markets for you. No need to travel or search for potential partners - come to BioBusiness Network to start the profitable relationships you need in new markets
3) Over 60 top-level BD&L professionals and deal-making experts will share the benefit of their experience with you. Get an overview of the market and an understanding of what your potential partners are doing during detailed sessions.
4) Put your questions to our key speakers in a more intimate environment and make the most of the opportunity to meet with experts in your therapeutic area at new roundtables throughout the conference.
5) Join over 200 delegates and speakers at our informal dinner to relax after a long day and increase you informal networking time.
6) We are working with the industry to encourage more and more innovative biotechs to attend. Small biotechs can receive big discounts through their national associations. Please get in touch for more details.
7) This year we have got more European biotech CEOs on the agenda than ever before. Make sure you are here to meet with them and uncover new opportunities.
‘This was a meeting of the right size and focus to put together industry representatives with common goals and to allow sufficient time and space to have really meaningful discussions\'
Kay Wagoner, CEO, Icagen
2 New Focus Days!
Partnering Skills
Take part in 10 intensive sessions led by over 15 experts to really help you refine your partnering skills. Hear directly from big pharma such as Roche, Novartis and Pfizer on their own internal processes and learn first hand from biotechs completing key projects in critical areas. Add in expertise from in-house lawyers, commercial viewpoints from marketing experts and management coaching from the Greystone Partnership, and you really can\'t afford to miss this comprehensive day.
Emerging Markets
With a 14.7% growth rate in the period 2005-2006, emerging markets are a key area both for sourcing innovation and forming lucrative collaborations. At this unique day you will have unrivalled access to potential partners in key emerging markets across the globe, including India, China, Latin America and CEE, all in one place. Book your place now to ensure you gain access to these potential partners.
What are you waiting for?
Booking is easy, just
Call +44 (0)20 7368 9465
Email biobusiness@wbr.co.uk
Visit www.biobusinessnetwork.com
To make any comments on this article, or to ask a question of the author, please contact the publisher. If you would like to submit an article, please contact the editors.
The opinions expressed in the articles published in this section do not necessarily reflect those of Pharmalicensing or UTEK Corporation. No actions including proposals to or agreements with other companies should be taken by any reader without obtaining specific business or legal advice. Neither the publisher nor the authors accept any liability for any actions or activities undertaken by any reader or other third party as a consequence of these articles or for any errors or omissions therein.